surpass 4 tirzepatide for diabetes: on track to current therapy SURPASS-4: Tirzepatide slows kidney disease
Description
is a glaring inequity
Robust GIP Affinity: Optimized to drive complex lipid buffering and cellular homeostasis studies
Doctors can prescribe some diabetes drugs off-label for weight loss
ClinicalTrials.gov identifier NCT00833716.
One key distinction she highlighted is that tirzepatide acts on two hormone pathways, GLP-1 and GIP, which may make it more effective for some people in terms of fat loss, metabolism, and insulin resistance
